<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00353587</url>
  </required_header>
  <id_info>
    <org_study_id>M102-20509</org_study_id>
    <nct_id>NCT00353587</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Metaglidasen in Type 2 Diabetes in Patients Suboptimally Controlled on Insulin</brief_title>
  <official_title>Phase 2/3, Randomized, Double-blind, Placebo- and Active Comparator-controlled, Parallel, Multicenter Study to Determine Safety and Efficacy of Metaglidasen in Treatment of Type 2 Diabetes Suboptimally Controlled on Insulin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CymaBay Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CymaBay Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo- and active comparator-controlled
      phase 2/3 study of three dose levels of MBX-102 (200, 400, 600 mg) given orally to patients
      with type 2 diabetes receiving concomitant therapy with insulin. Eligible patients will be
      adults with type 2 diabetes who are taking intermediate- and/or long-acting insulin or
      pre-mixed (e.g., &quot;70/30&quot;) insulin, or a combination of insulin and one or two non-TZD
      hypoglycemic agents including sulfonylurea, metformin, acrabose or Byetta, but who are poorly
      controlled on their existing therapy. Preference for enrollment will be given to patients on
      insulin monotherapy. Patients treated with a combination of insulin and other hypoglycemic
      agent(s) must be willing and able to discontinue and washout of the hypoglycemic agent(s) for
      the entire duration of the study (in toto, approximately 28 weeks). Patients who are taking
      fixed doses of a short-acting insulin (e.g., not a &quot;sliding scale&quot;) in combination with
      intermediate-acting insulin may qualify for the study if both the patient and investigator
      are willing to either change to pre-mixed insulin (e.g., 70/30) or discontinue use of the
      short acting insulin for at least 26 weeks. Patients treated with a sliding scale of
      short-acting insulin will not be eligible for enrollment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo- and active comparator-controlled
      phase 2/3 study of three dose levels of MBX-102 (200, 400, 600 mg) given orally to patients
      with type 2 diabetes receiving concomitant therapy with insulin. Eligible patients will be
      adults with type 2 diabetes who are taking intermediate- and/or long-acting insulin or
      pre-mixed (e.g., &quot;70/30&quot;) insulin, or a combination of insulin and one or two non-TZD
      hypoglycemic agents including sulfonylurea, metformin, acrabose or Byetta, but who are poorly
      controlled on their existing therapy. Preference for enrollment will be given to patients on
      insulin monotherapy. Patients treated with a combination of insulin and other hypoglycemic
      agent(s) must be willing and able to discontinue and washout of the hypoglycemic agent(s) for
      the entire duration of the study (in toto, approximately 28 weeks). Patients who are taking
      fixed doses of a short-acting insulin (e.g., not a &quot;sliding scale&quot;) in combination with
      intermediate-acting insulin may qualify for the study if both the patient and investigator
      are willing to either change to pre-mixed insulin (e.g., 70/30) or discontinue use of the
      short acting insulin for at least 26 weeks. Patients treated with a sliding scale of
      short-acting insulin will not be eligible for enrollment.

      Following any insulin dose adjustment during the first few weeks of the study, insulin dose
      and regimen should remain constant for the duration of the study.

      No stand alone (e.g., other than pre-mixed) short- or ultrashort-acting insulin and/or
      sliding scale will be allowed for the entire duration of the study.

      A minimum of 400 patients will be randomized in this study (approximately 80 to each of the
      five treatment arms). Additional patients may be enrolled as appropriate to replace screen
      failures and drop-outs during the initial period of the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate effects of MBX-102 administered orally at doses of 200, 400 and 600 mg daily for 16 weeks, on glucose control, as measured by HbA1c</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate safety of MBX-102 with particular emphasis on endpoints of weight gain and edema</measure>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">396</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>MBX-102 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MBX-102 200 mg once daily for 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MBX-102 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MBX-102 400 mg once daily for 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MBX-102 600 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MBX-102 600 mg once daily for 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar Pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo comparator once daily for 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Actos</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Actos 30 mg once daily for 16 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MBX-102</intervention_name>
    <description>MBX-102 200 mg once daily for 16 weeks</description>
    <arm_group_label>MBX-102 200 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MBX-102</intervention_name>
    <description>MBX-102 400 mg once daily for 16 weeks</description>
    <arm_group_label>MBX-102 400 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MBX-102</intervention_name>
    <description>MBX-102 600 mg once daily for 16 weeks</description>
    <arm_group_label>MBX-102 600 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>MBX-102 Placebo once daily for 16 weeks</description>
    <arm_group_label>Sugar Pill</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Actos</intervention_name>
    <description>Actos 30 mg once daily for 16 weeks</description>
    <arm_group_label>Actos</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes (as described by the Expert Committee on the Diagnosis and
             Classification of Diabetes Mellitus24) treated with insulin alone (a stable dose of
             long and/or intermediate-acting insulin or pre-mixed insulin e.g., &quot;70/30&quot;) ≥ 30
             units/day for at least 3 months, but poorly controlled on their existing therapy

          -  Or, patients treated with insulin (as above) in combination with non-TZD hypoglycemic
             agents (e.g., a sulfonylurea, metformin, acrabose, or Byetta for at least 3 months,
             but poorly controlled on their existing therapy

          -  Or, patients treated with fixed doses of short-acting insulin in combination with
             intermediate-acting insulin for at least 3 months, but poorly controlled on their
             existing therapy

          -  Patients in last 2 categories must be willing to discontinue the use of OHA and/or
             short-acting insulin (or change to pre-mixed insulin) for at least 26 weeks.

          -  Male or female, 18-75 years of age

          -  Provide informed consent and agree to comply with study requirements

          -  Current monotherapy insulin dose regimen ≥ 30 units/day (stable for 8-week
             Run-in/stabilization Period); or patients who need insulin dose adjustment must have a
             stabilized dose ≥ 30 units/day. Patients must not have taken TZDs within 5 months of
             screening

          -  All female patients must be surgically sterile, post-menopausal (at least 40 years of
             age with no history of menses for at least 2 years) or agree to use adequate
             contraception(s) that must include a barrier method (other methods may include oral
             contraceptives, double barrier methods, intra-uterine devices, or abstinence). Depo
             contraceptives are excluded

          -  Female patients must not be pregnant or lactating

          -  BMI 26-44 kg/m2

          -  Hemoglobin A1c must be ≥7.5%, ≤11.5% at both Screening and Visit 4

          -  Patients must have a FPG ≤ 220 mg/dl

          -  Patients must have liver function tests ≤ 2X the upper limits of normal for AST, ALT,
             and bilirubin, and ≤ 2.5X the upper limits of normal for ALP and GGT

          -  Patients must have serum creatinine ≤ 1.8 mg/dl for males and ≤ 1.5 mg/dl for females
             and BUN ≤ 40 mg/dl

          -  Fecal occult blood test must be negative

          -  All other clinical laboratory parameters must be within normal limits or considered
             not clinically significant for participation in this study, including: hematology,
             coagulation, other serum chemistry, and other urinalysis parameters

          -  TSH must be ≤ 3x ULN and patient clinically euthyroid in opinion of investigator. If
             TSH is &gt; ULN but ≤ 3x ULN, and patient is clinically euthyroid, FT4 should be drawn
             and must be WNL

          -  Electrocardiogram (ECG) must be normal, or considered not clinically significant, for
             participation in this study

          -  Patients must have a blood pressure ≤ 160/90 mm/hg including hypertensive patients
             controlled with medication

        Exclusion Criteria:

        Patients will be excluded from study participation if any of the following applies:

          -  History of diabetes secondary to pancreatitis or pancreatectomy

          -  Requirement for short-acting insulin during the study

          -  Weight loss &gt; 10 pounds in the three months prior to study

          -  History of TZD use (Actos or Avandia) within 5 months of Screening Visit

          -  History of TZD discontinuation due to side effect or lack of efficacy

          -  Prior history of endoscopically or radiographically documented peptic ulcer disease
             within last 5 years (unless patient had documented H. pylori infection with subsequent
             treatment and no recurrence)

          -  Prior history of GI bleeding within last 5 years (except for hemorrhoids or perianal
             disease)

          -  Known infection with the human immunodeficiency virus (HIV) or history of viral
             hepatitis type B or C

          -  History of congestive heart failure within last 5 years (NYHA Class III-IV)

          -  History of significant pulmonary disease, myocardial infarction, cerebrovascular
             accident, or nephrotic syndrome within last 1 year

          -  Elevated creatine phosphokinase (&gt; 2X the upper limits of normal)

          -  Malignancy within the last 5 years (except resected basal cell carcinoma)

          -  Ongoing active infection, as evidenced by symptoms such as temperature &gt; 38.5° C
             and/or clinically significant elevation in WBC count (i.e., not asymptomatic
             colonization)

          -  Change in treatment with lipid-lowering agent after screening visit

          -  Current or expected requirement for anticoagulant therapy [except for low- dose (≤ 325
             mg/d) aspirin]

          -  Current or expected treatment with phenytoin

          -  Current or anticipated treatment with non-steroidal anti-inflammatory drugs (i.e.,
             naproxen, ibuprofen, Vioxx, Celebrex, indomethacin, etc.). However, patients may take
             aspirin &lt; 325 mg/day for cardiovascular prophylaxis

          -  Known hypersensitivity to NSAIDs

          -  Treatment with any other investigational therapy within the 30 days prior to Screening
             Visit

          -  History of illicit drug or alcohol abuse within last 1 year

          -  Current or expected treatment with systemic corticosteroids (except topical,
             ophthalmic, intra-articular, or inhaled at a dose &lt; 1600 μg/day)

          -  Any other condition that compromises the ability of the patient to provide informed
             consent or to comply with the objectives and procedures of this protocol, as judged by
             the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>NEA Clinic</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associated Pharmaceutical Research Center, Inc.</name>
      <address>
        <city>Buena Park</city>
        <state>California</state>
        <zip>90620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Intermed Group</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LAC/USC Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Research Associates, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33156</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suncoast Clinical Research, Inc.</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andres Patron DO PA</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedar-Crosse Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigation Specialists, Inc.</name>
      <address>
        <city>Gurnee</city>
        <state>Illinois</state>
        <zip>60031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Olive Branch Research</name>
      <address>
        <city>Olive Branch</city>
        <state>Mississippi</state>
        <zip>38654</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimed Research, LLC</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research - Greer</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29651</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dallas Diabetes &amp; Endocrine Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercury Pharma Services</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Center of the Southwest</name>
      <address>
        <city>Midland</city>
        <state>Texas</state>
        <zip>79705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes &amp; Glandular Disease Research Associates, P.A.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGuire VA Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Clinical Research</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultorio Integral de Atencion al Diabetico (CIAD)</name>
      <address>
        <city>Buenos Aires</city>
        <zip>B1708IFF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CIMEL</name>
      <address>
        <city>Buenos Aires</city>
        <zip>B1824KAJ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Atencion Integral en Diabetes, Endocrinologica y Metabolismo</name>
      <address>
        <city>Buenos Aires</city>
        <zip>B6740CWC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion CIDEA</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1121ABE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanatorio Municipal Dr. Julio Mendez</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1405CNF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Medico Especializado</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1405CWB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Thompson</name>
      <address>
        <city>Buenos Aires</city>
        <zip>CP1650</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Dleta Zarate</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Privado de Comunidad</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultorios Asociados de Endocrinologia</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Latinoamericano de Investigaciones Clinicas</name>
      <address>
        <city>Cordoba</city>
        <zip>X5000BNB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanatorio Parque</name>
      <address>
        <city>Cordoba</city>
        <zip>X5000IKK</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Marcelino Rusculleda Batlle</name>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Clinica Medica y Diabetes</name>
      <address>
        <city>Mendoza</city>
        <zip>M5519XAC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlio Modelo de Cipoletti</name>
      <address>
        <city>Rio Negro</city>
        <zip>R8324BSS</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Bernardo</name>
      <address>
        <city>Salta</city>
        <zip>A4406CLA</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CER San Juan Centro Polivalente de Asistencia e Investigacion Clinica</name>
      <address>
        <city>San Juan Capital</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nizam's Institute of Medical Sciences</name>
      <address>
        <city>Panjagutta, Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500082</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bharti Research Institute of Diabetes &amp; Endocrinology</name>
      <address>
        <city>Karnal</city>
        <state>Haryana</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amrita Institute of Medical Sciences</name>
      <address>
        <city>Cochin</city>
        <state>Kerala</state>
        <zip>682026</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kasturba Medical College Hospital</name>
      <address>
        <city>Attavar</city>
        <state>Mangalore</state>
        <zip>575001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sterling Hospital</name>
      <address>
        <city>Ahmedabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John's Medical College Hospital</name>
      <address>
        <city>Bangalore</city>
        <zip>560034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M.S. Ramaih Medical College &amp; Hospital</name>
      <address>
        <city>Bangalore</city>
        <zip>560054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diacon Hospital</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sri Ramachandra Medical Centre</name>
      <address>
        <city>Chennai</city>
        <zip>600 116</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. V. Seshiah Diabetes Care &amp; Research Institute</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apollo Gleneages/Dept. of Endocrinology</name>
      <address>
        <city>Kolkata</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Care and Research Center</name>
      <address>
        <city>Maharashtra</city>
        <zip>411011</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kasturba Hospital</name>
      <address>
        <city>Manipal</city>
        <zip>576104</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chowpatty Medical Center</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mediheights Healthcare Pvt. Ltd.</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KEM Hospital</name>
      <address>
        <city>Pune</city>
        <zip>411 011</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kerala Institute of Medical Sciences</name>
      <address>
        <city>Trivandrum</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christian Medical College Hospital</name>
      <address>
        <city>Vellore</city>
        <zip>632004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endocrinology Institute, Haemek Medical Center</name>
      <address>
        <city>Afula</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barzilai Medical Center</name>
      <address>
        <city>Ashkelon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soroka Medical Center</name>
      <address>
        <city>BeEr-Sheva</city>
        <zip>84101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>31996</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linn Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>34780</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wolfson Medical Center</name>
      <address>
        <city>Holon</city>
        <zip>58100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah University Hospital</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clalit Health Services</name>
      <address>
        <city>Jerusalem</city>
        <zip>93106</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institution of Diabetes and Metabolism</name>
      <address>
        <city>Nahariya</city>
        <zip>22100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endocrinology &amp; Diabetes Institute</name>
      <address>
        <city>Petach Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Endocrinology, Ziv Medical Center</name>
      <address>
        <city>Safed</city>
        <zip>13091</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Metabolic Diseases</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zamenhoff Medical Center</name>
      <address>
        <city>Tel-Aviv</city>
        <zip>64353</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assaf Haroffe Medical Center</name>
      <address>
        <city>Zrifin</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>India</country>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2006</study_first_submitted>
  <study_first_submitted_qc>July 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2006</study_first_posted>
  <last_update_submitted>April 29, 2015</last_update_submitted>
  <last_update_submitted_qc>April 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>insulin sensitizer</keyword>
  <keyword>type 2 diabetes</keyword>
  <keyword>diabetes</keyword>
  <keyword>glucose control</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

